EE200000438A - Farmatseutiliselt aktiivne morfolinool - Google Patents

Farmatseutiliselt aktiivne morfolinool

Info

Publication number: EE200000438A
Authority: EE; Estonia
Prior art keywords: pharmaceutically active; morpholinol; active morpholinol; pharmaceutically; active
Prior art date: 1998-01-21

Application number

EEP200000438A

Other languages

English (en)

Inventor

Frederick Morgan Phillip

Lee Musso David

Joseph Partridge John

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

1999-01-20

Publication date

2001-12-17

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

1999-01-20 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2001-12-17 Publication of EE200000438A publication Critical patent/EE200000438A/et

2005-04-15 Publication of EE04452B1 publication Critical patent/EE04452B1/et

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EEP200000438A 1998-01-21 1999-01-20 Farmatseutiliselt aktiivne morfolinool ja selle kasutamine EE04452B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22
PCT/US1999/001134 WO1999037305A1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Publications (2)

Publication Number	Publication Date
EE200000438A true EE200000438A (et)	2001-12-17
EE04452B1 EE04452B1 (et)	2005-04-15

Family

ID=26312986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000438A EE04452B1 (et)	1998-01-21	1999-01-20	Farmatseutiliselt aktiivne morfolinool ja selle kasutamine

Country Status (30)

Country	Link
US (2)	US6274579B1 (et)
EP (2)	EP1829544A1 (et)
JP (1)	JP2002501025A (et)
KR (1)	KR100568063B1 (et)
CN (2)	CN1203858C (et)
AP (1)	AP1229A (et)
AT (1)	ATE365042T1 (et)
AU (1)	AU755536B2 (et)
BR (1)	BR9907203A (et)
CA (1)	CA2318268A1 (et)
CY (1)	CY1106828T1 (et)
DE (1)	DE69936335T2 (et)
DK (1)	DK1047428T3 (et)
EA (1)	EA002410B1 (et)
EE (1)	EE04452B1 (et)
ES (1)	ES2288012T3 (et)
HR (2)	HRP20000494B1 (et)
HU (1)	HUP0100900A3 (et)
ID (1)	ID26334A (et)
IL (2)	IL137346A0 (et)
IS (1)	IS2494B (et)
NO (2)	NO326878B1 (et)
NZ (3)	NZ505809A (et)
PL (1)	PL193622B1 (et)
PT (1)	PT1047428E (et)
SG (1)	SG115489A1 (et)
SK (1)	SK10912000A3 (et)
TR (1)	TR200002126T2 (et)
WO (1)	WO1999037305A1 (et)
YU (1)	YU67102A (et)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en) *	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
AU2483599A (en)	1998-01-29	1999-08-16	Sepracor, Inc.	Pharmaceutical uses of optically pure (-)-bupropion
WO1999038503A1 (en)	1998-01-29	1999-08-05	Sepracor Inc.	Pharmacological uses of optically pure (+)-bupropion
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
JP2003511410A (ja) *	1999-10-13	2003-03-25	グラクソグループリミテッド	肥満症の治療のためのモルホリノール誘導体
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
US7145649B2 (en) *	2000-12-21	2006-12-05	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
EP1505967B1 (en) *	2002-05-17	2016-07-13	Duke University	Method for treating obesity
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
DE60324685D1 (de) *	2002-08-23	2008-12-24	Lilly Co Eli	2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
HUE034290T2 (en)	2003-04-29	2018-02-28	Orexigen Therapeutics Inc	Preparations containing opioid antagonist and bupropion to affect weight loss
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
US20070093486A1 (en) *	2003-10-27	2007-04-26	Smith Kline Beecham Corporation ,Corporation	Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US7429580B2 (en)	2004-01-13	2008-09-30	Orexigen Therapeutics, Inc.	Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
WO2005110405A1 (en) *	2004-05-03	2005-11-24	Duke University	Compositions for affecting weight loss
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
CA2630624C (en)	2005-11-22	2013-08-06	Orexigen Therapeutics, Inc.	Compositions and methods for increasing insulin sensitivity
WO2007079470A2 (en) *	2006-01-03	2007-07-12	Algebra, Inc.	Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
CN101573103A (zh)	2006-11-09	2009-11-04	奥雷西根治疗公司	用于施用重量减轻药物的单位剂量包装和方法
JP2010509367A (ja)	2006-11-09	2010-03-25	オレキシジェン・セラピューティクス・インコーポレーテッド	積層製剤
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
WO2010121022A1 (en)	2009-04-15	2010-10-21	Research Triangle Institute	Monoamine reuptake inhibitors
JP6196041B2 (ja)	2010-01-11	2017-09-13	オレキシジェン・セラピューティクス・インコーポレーテッド	大うつ病を有する患者において減量療法を提供する方法
ES2546492T3 (es)	2010-05-21	2015-09-24	Research Triangle Institute	Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia
CA2800220C (en)	2010-05-21	2019-04-30	Research Triangle Institute	Phenylmorpholines and analogues thereof
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20230010811A (ko)	2012-06-06	2023-01-19	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) *	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en active IP Right Grant
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 EE EEP200000438A patent/EE04452B1/et not_active IP Right Cessation
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
- 2000-07-21 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2005
- 2005-12-29 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DK1047428T3 (da)	2007-10-08
EE04452B1 (et)	2005-04-15
NO20083529L (no)	2000-09-19
AP2000001869A0 (en)	2000-09-30
HRP20000494A2 (en)	2000-12-31
US6274579B1 (en)	2001-08-14
JP2002501025A (ja)	2002-01-15
IL137346A0 (en)	2001-07-24
HRP20051024A2 (hr)	2006-04-30
CN1528753A (zh)	2004-09-15
CN1255389C (zh)	2006-05-10
EA002410B1 (ru)	2002-04-25
US20020019396A1 (en)	2002-02-14
DE69936335D1 (de)	2007-08-02
NZ505809A (en)	2002-09-27
BR9907203A (pt)	2000-10-17
ATE365042T1 (de)	2007-07-15
IS5568A (is)	2000-07-20
AP1229A (en)	2003-12-04
CN1294513A (zh)	2001-05-09
HRP20000494B1 (en)	2009-02-28
AU755536B2 (en)	2002-12-12
EP1829544A1 (en)	2007-09-05
NZ520349A (en)	2004-02-27
HUP0100900A3 (en)	2002-08-28
DE69936335T2 (de)	2008-02-28
TR200002126T2 (tr)	2000-12-21
IS2494B (is)	2009-02-15
ID26334A (id)	2000-12-14
KR20010034285A (ko)	2001-04-25
IL161942A0 (en)	2005-11-20
CY1106828T1 (el)	2012-05-23
HUP0100900A2 (hu)	2002-05-29
PL193622B1 (pl)	2007-02-28
NO20003721L (no)	2000-09-19
EA200000691A1 (ru)	2001-04-23
CA2318268A1 (en)	1999-07-29
SG115489A1 (en)	2005-10-28
EP1047428B1 (en)	2007-06-20
US6391875B2 (en)	2002-05-21
NO326878B1 (no)	2009-03-09
YU67102A (sh)	2004-12-31
EP1047428A1 (en)	2000-11-02
CN1203858C (zh)	2005-06-01
NO20003721D0 (no)	2000-07-20
SK10912000A3 (sk)	2001-04-09
NZ529316A (en)	2004-05-28
ES2288012T3 (es)	2007-12-16
PL342012A1 (en)	2001-05-07
AU2328099A (en)	1999-08-09
EP1047428A4 (en)	2001-12-19
KR100568063B1 (ko)	2006-04-07
WO1999037305A1 (en)	1999-07-29
PT1047428E (pt)	2007-09-07

Publication	Publication Date	Title
NO20003721D0 (no)	2000-07-20	Farmasøytisk aktivt morfolinol
PT1220856E (pt)	2005-02-28	Compostos farmaceuticamente activos
NL350038I2 (nl)	2009-01-05	Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazolinederivaten
DE69926752D1 (de)	2005-09-22	Therapeutisch wirksame biaryl-derivate
GB9823101D0 (en)	1998-12-16	Pharmaceutically active compounds
DE50007846D1 (de)	2004-10-28	Dreschkorb
DE60009395D1 (de)	2004-05-06	Bildanzeige
MA26473A1 (fr)	2004-12-20	Composes pharmacologiquement actifs.
DK1218374T3 (da)	2005-12-27	Farmaceutisk aktive sulfonamidderivater
NO992692D0 (no)	1999-06-03	Nefadozon doseringsform
GB9823102D0 (en)	1998-12-16	Pharmaceutically active compounds
NO993443D0 (no)	1999-07-13	Kabinstruktur
DE50015795D1 (de)	2009-12-24	Sektionaltor
NO20012965D0 (no)	2001-06-15	Sulfonyloksazolaminer som terapeutisk aktive forbindelser
DE59902159D1 (de)	2002-08-29	Aktiver mikromischer
FI991568L (fi)	1999-07-08	Farmaseuttisesti aktiivisia trisyklisiä amiineja
NO20005769D0 (no)	2000-11-14	Cyklosporinderivater
EP1157700A4 (en)	2003-06-18	ANTI-HIV SUBSTANCE
SE9802539D0 (sv)	1998-07-13	New pharmaceutically active compounds
IS8740A (is)	2008-06-27	Lyfjafræðilega virkt morfólínól
SE9700660D0 (sv)	1997-02-25	Pharmaceutically active compounds
ATA203199A (de)	2001-03-15	Ablauf
SE9704874D0 (sv)	1997-12-23	New pharmaceutically active compounds
DE60004561D1 (de)	2003-09-18	Aktive baugruppe
SE9901854D0 (sv)	1999-05-21	New pharmaceutically active compounds

Legal Events

Date	Code	Title	Description
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2013-10-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20130120